Intravitreal injections: past trends and future projections within a UK tertiary hospital
Open accessThe DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Abstract
Aims: To describe past trends and future projections for the number of intravitreal injections being administered at a large tertiary hospital in London, United Kingdom. Methods: Retrospective data from Moorfields Eye Hospital were collected using the electronic medical record system. Descriptive statistics were used to visualise overall trends. Time series forecasting was used to predict the number of injections that will be administered up to and including the year 2029. Results: The number of injections has increased nearly 11-fold from 2009 to 2019, with a total of 44,924 injections delivered in 2019. The majority of injections were given for the treatment of neovascular age-related macular degeneration. Aflibercept formed 87% of injections administered in 2019. The number of injections is predicted to continue to increase every year, with nearly 83,000 injections forecasted in the year 2029. Conclusion: The demand for intravitreal injections has increased substantially over the last decade and is predicted to further increase. Healthcare systems will need to adapt to accommodate the high demand. Other solutions may include longer-acting therapies to reduce the treatment burden.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Research has suggested that the delivery of anti-VEGF injections is a major cost-driver and is expected to increase over time [12, 50, 67, 68].”
From The economic impact of retinal diseases for which gene therapy is emerging: a systematic literature review (2025) · cites this paper as [68]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Other studies showed a similar trend regarding the increase in the number of anti-VEGF injections, which is projected to become even greater in the future [12, 68].”
From The economic impact of retinal diseases for which gene therapy is emerging: a systematic literature review (2025) · cites this paper as [68]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
De Cillà, S. D., Farruggio, S., Vujosevic, S., Raina, G., Filippini, D., Gatti, V., Clemente, N., Mary, D., Vezzola, D., Casini, G., et al. (2017) · Cellular Physiology and Biochemistry · doi:10.1159/000479441 · Cited by 5,136
Taylor, S. J., & Letham, B. (2018) · The American Statistician · doi:10.1080/00031305.2017.1380080 · Cited by 2,737
Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration
Heier, J. S., Brown, D. M., Chong, V., Korobelnik, J.-F., Kaiser, P. K., Nguyen, Q. D., Kirchhof, B., Ho, A., Ogura, Y., Yancopoulos, G. D., et al. (2012) · Ophthalmology · doi:10.1016/j.ophtha.2012.09.006 · Cited by 2,485
Dugel, P. U., Koh, A., Ogura, Y., Jaffe, G. J., Schmidt-Erfurth, U., Brown, D. M., Gomes, A. V., Warburton, J., Weichselberger, A., & Holz, F. G. (2020) · Ophthalmology · doi:10.1016/j.ophtha.2019.04.017 · Cited by 931
Chakravarthy, U., Harding, S. P., Rogers, C. A., Downes, S. M., Lotery, A. J., Culliford, L. A., & Reeves, B. C. (2013) · The Lancet · doi:10.1016/s0140-6736(13)61501-9 · Cited by 748
Maguire, M. G., Martin, D. F., Ying, G.-S., Jaffe, G. J., Daniel, E., Grunwald, J. E., Toth, C. A., Ferris, F. L., & Fine, S. L. (2016) · Ophthalmology · doi:10.1016/j.ophtha.2016.03.045 · Cited by 708
Liao, D. S., Grossi, F. V., El Mehdi, D., Gerber, M. R., Brown, D. M., Heier, J. S., Wykoff, C. C., Singerman, L. J., Abraham, P., Grassmann, F., et al. (2020) · Ophthalmology · doi:10.1016/j.ophtha.2019.07.011 · Cited by 519
C5 Inhibitor Avacincaptad Pegol for Geographic Atrophy Due to Age-Related Macular Degeneration
Jaffe, G. J., Westby, K., Csaky, K. G., Monés, J., Pearlman, J. A., Patel, S. S., Joondeph, B. C., Randolph, J., Masonson, H., & Rezaei, K. A. (2021) · Ophthalmology · doi:10.1016/j.ophtha.2020.08.027 · Cited by 469
Sivaprasad, S., Prevost, A. T., Vasconcelos, J. C., Riddell, A., Murphy, C., Kelly, J., Bainbridge, J., Tudor-Edwards, R., Hopkins, D., Hykin, P., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31193-5 · Cited by 390
Li, J. Q., Welchowski, T., Schmid, M., Mauschitz, M. M., Holz, F. G., & Finger, R. P. (2020) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2019-314422 · Cited by 381
Research works printed but not linked: 1
- Wickham L, Hay G, Hamilton R, Wooding J, Tossounis H, da Cruz L, et al. The impact of COVID policies on acute. Ophthalmol Serv-experiences Moorfields Eye Hospital NHS Found Trust Eye. 2020;34:1189–92.
Cited by
Liberski, S., Wichrowska, M., & Kocięcki, J. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23169424 · Cited by 139
“Another widely used anti-VEGF drug, bevacizumab, is used intravitreally as an off-label drug [6].”
BackgroundRaimondi, R., Felfeli, T., Bogdanova-Bennet, A., Varma, D., Habib, M., Kotagiri, A. K., STEEL, D. H., & Grinton, M. E. (2023) · Ophthalmology Retina · doi:10.1016/j.oret.2023.11.015 · Cited by 62
Risk of Endophthalmitis Based on Cumulative Number of Anti-VEGF Intravitreal Injections
Israilevich, R. N., Mansour, H. A., PATEL, S. N., Garg, S. J., Klufas, M. A., Yonekawa, Y., Regillo, C. D., & Hsu, J. (2024) · Ophthalmology · doi:10.1016/j.ophtha.2023.12.033 · Cited by 47
Wang, R., McClard, C. K., Laswell, S. M., Mahmoudzadeh, R., Salabati, M., Ammar, M. J., Vannavong, J., Aziz, A. A., Ewald, A., Calvanese, A. V., et al. (2022) · BMJ Open Ophthalmology · doi:10.1136/bmjophth-2022-001188 · Cited by 51
Hashimoto, Y., Okada, A., Matsui, H., Yasunaga, H., Aihara, M., & Obata, R. (2022) · Japanese Journal of Ophthalmology · doi:10.1007/s10384-022-00969-2 · Cited by 46
“Trends in the use of anti-VEGF are reported in various countries, the US [14, 15], the UK [16], and Italy [17].”
Background
Metadata
- Authors
- Chopra, R., Preston, G. C., Keenan, T. D. L., Mulholland, P., Patel, P. J., Balaskas, K., Hamilton, R. D., & Keane, P. A.
- Affiliations
- Moorfields Eye Hospital NHS Foundation Trust (GB)
- Corresponding author
- Keane, Pearse A.
- ORCID
- Venue
- Eye
- Published
- 2021-06-25
- Volume
- 36
- Issue
- 7
- Pages
- 1373-1378
- ISSN
- 0078-5334 (ISSN-L)
- 0950-222X
- 1476-5454
- PMC
- PMC8227364
- OpenAlex
- W3173934490
- Cited by
- 83
- References
- 26
- Citations by year
- 2026: 22 · 2025: 16 · 2024: 21 · 2023: 12 · 2022: 12
- FWCI
- 10.30
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Eye (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Ulster University Research Portal (Ulster University) (submittedVersion, cc-by)
- Funders
- College of Optometrists
- U.S. Department of Health & Human Services | National Institutes of Health
- Topics
- Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
- Health Sciences › Medicine › Ophthalmology › Retinal and Macular Surgery
- Health Sciences › Medicine › Ophthalmology › Ocular Diseases and Behçet’s Syndrome
- Keywords
- intravitreal injection, neovascular age-related macular degeneration, aflibercept, time series forecasting, healthcare resource planning, Moorfields Eye Hospital
- MeSH terms
- Ranibizumab, Follow-Up Studies, Humans, Population Growth, Recombinant Fusion Proteins, Retrospective Studies, Visual Acuity, Treatment Outcome, Angiogenesis Inhibitors, Receptors, Vascular Endothelial Growth Factor, Intravitreal Injections, Tertiary Care Centers
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Intravitreal injections: past trends and future projections within a UK tertiary hospital. https://app.cochat.ai/papers/10.1038/s41433-021-01646-3
- The paper
- Chopra, R., Preston, G. C., Keenan, T. D. L., Mulholland, P., Patel, P. J., Balaskas, K., Hamilton, R. D., & Keane, P. A. (2022). Intravitreal injections: past trends and future projections within a UK tertiary hospital. Eye. https://doi.org/10.1038/s41433-021-01646-3
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.